Respiratory Infections News

A small cohort of patients at a Tennessee hospital who met the criteria for multisystem inflammatory syndrome in adults experienced broader organ involvement and were less ill compared with patients in a previous report, researchers said.

In a recent paper published in Science, researchers argued for a “paradigm shift” in how policymakers and building engineers approach indoor air quality and health in order to reduce the spread of respiratory infections.

CDC investigators identified just 10,262 breakthrough SARS-CoV-2 infections in 46 U.S. states as of April 30, when approximately 101 million Americans had been fully vaccinated, according to results published today in MMWR.

Moderna said Tuesday that its COVID-19 vaccine was safe and “highly effective” in a phase 2/3 study among adolescents aged 12 to 17 years, offering a level of protection in the younger age group akin to that seen in adults.

The CDC’s COVID-19 vaccine safety group recently reviewed what it said were “relatively few reports” of myocarditis among young recipients of the messenger RNA-based COVID-19 vaccines.

A follow-up analysis of the CORIMUNO-TOCI-1 randomized clinical trial showed that tocilizumab may be considered for treating patients with moderate-to-severe COVID-19-associated pneumonia and high C-reactive protein levels.

Researchers found an association between region of birth and time to diagnosis among foreign-born people in the U.S. with tuberculosis, suggesting that where a person was born may predict progression from latent TB to TB disease, they said.

Mask requirements and upgrades to ventilation reduced the incidence of COVID-19 in Georgia elementary schools by up to almost half, data published in MMWR showed.

Experts have worked to reassure people that the benefits of COVID-19 vaccination outweigh the risks, which primarily include short-lived reactions.

Merck’s investigational V114 pneumococcal conjugate vaccine, which includes 15 serotypes, met its primary immunogenicity and safety endpoints in two phase 3 pediatric trials, the company announced.